 Francisco La Rosa
Concepts (430)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 22 | 2022 | 999 | 2.460 |
Why?
| | Urinary Bladder Neoplasms | 8 | 2024 | 226 | 1.660 |
Why?
| | Prostate | 9 | 2022 | 173 | 1.340 |
Why?
| | Kidney Neoplasms | 10 | 2014 | 347 | 1.090 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2015 | 627 | 0.720 |
Why?
| | Prostatectomy | 9 | 2022 | 103 | 0.680 |
Why?
| | Carcinoma, Papillary | 3 | 2015 | 77 | 0.600 |
Why?
| | Adenocarcinoma | 4 | 2014 | 893 | 0.590 |
Why?
| | Solitary Fibrous Tumors | 1 | 2017 | 3 | 0.550 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2015 | 55 | 0.540 |
Why?
| | Carcinoma, Basal Cell | 2 | 2014 | 74 | 0.520 |
Why?
| | Carcinoma, Renal Cell | 3 | 2013 | 178 | 0.510 |
Why?
| | Spectrum Analysis | 1 | 2016 | 89 | 0.500 |
Why?
| | Thyroid Gland | 9 | 2000 | 95 | 0.480 |
Why?
| | Biopsy | 8 | 2019 | 1087 | 0.450 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2014 | 59 | 0.440 |
Why?
| | Parturition | 1 | 2014 | 71 | 0.440 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2013 | 7 | 0.430 |
Why?
| | Carcinoma, Medullary | 1 | 2013 | 14 | 0.430 |
Why?
| | Biopsy, Needle | 7 | 2016 | 187 | 0.390 |
Why?
| | Seasons | 1 | 2014 | 493 | 0.380 |
Why?
| | Neoplasm Grading | 7 | 2022 | 283 | 0.380 |
Why?
| | Neoplasm Invasiveness | 5 | 2024 | 483 | 0.370 |
Why?
| | Lymph Node Excision | 3 | 2024 | 164 | 0.360 |
Why?
| | Cystectomy | 2 | 2024 | 38 | 0.360 |
Why?
| | Neoplasm Staging | 6 | 2024 | 1281 | 0.340 |
Why?
| | Urothelium | 3 | 2015 | 37 | 0.340 |
Why?
| | Male | 55 | 2024 | 63691 | 0.330 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2021 | 70 | 0.330 |
Why?
| | Skin Neoplasms | 2 | 2014 | 829 | 0.330 |
Why?
| | Cyclic AMP | 7 | 2000 | 238 | 0.320 |
Why?
| | Aged | 22 | 2024 | 22101 | 0.320 |
Why?
| | Mediastinal Diseases | 1 | 2007 | 10 | 0.290 |
Why?
| | Carcinoid Tumor | 1 | 2007 | 24 | 0.280 |
Why?
| | Melanoma | 1 | 2014 | 730 | 0.280 |
Why?
| | Neuroblastoma | 8 | 2010 | 151 | 0.270 |
Why?
| | Parotid Gland | 7 | 1999 | 22 | 0.260 |
Why?
| | Ubiquitins | 4 | 2000 | 36 | 0.250 |
Why?
| | Humans | 60 | 2024 | 129687 | 0.250 |
Why?
| | Sarcoidosis | 1 | 2007 | 157 | 0.240 |
Why?
| | Cell Division | 6 | 2000 | 790 | 0.240 |
Why?
| | Italy | 5 | 2014 | 99 | 0.220 |
Why?
| | Lymphatic Diseases | 2 | 2009 | 21 | 0.220 |
Why?
| | Finasteride | 3 | 2008 | 34 | 0.210 |
Why?
| | Middle Aged | 23 | 2024 | 31165 | 0.210 |
Why?
| | Image-Guided Biopsy | 2 | 2012 | 37 | 0.200 |
Why?
| | Cell Transplantation | 3 | 1997 | 37 | 0.200 |
Why?
| | Prognosis | 6 | 2019 | 3772 | 0.200 |
Why?
| | Major Histocompatibility Complex | 5 | 1990 | 229 | 0.190 |
Why?
| | Urinary Bladder | 2 | 2014 | 175 | 0.190 |
Why?
| | Prostate-Specific Antigen | 7 | 2020 | 160 | 0.180 |
Why?
| | Antigens, Polyomavirus Transforming | 3 | 1998 | 18 | 0.180 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2021 | 25 | 0.180 |
Why?
| | Seminoma | 1 | 2021 | 18 | 0.180 |
Why?
| | Immunohistochemistry | 2 | 2017 | 1690 | 0.180 |
Why?
| | Graft Rejection | 8 | 1990 | 598 | 0.180 |
Why?
| | Biomarkers, Tumor | 3 | 2020 | 1161 | 0.180 |
Why?
| | Lymph Nodes | 4 | 2015 | 471 | 0.170 |
Why?
| | Diagnosis, Differential | 6 | 2015 | 1433 | 0.170 |
Why?
| | Teratoma | 1 | 2021 | 103 | 0.170 |
Why?
| | Imaging, Three-Dimensional | 2 | 2015 | 529 | 0.170 |
Why?
| | Testicular Neoplasms | 1 | 2021 | 102 | 0.170 |
Why?
| | Pyrroles | 2 | 2013 | 202 | 0.160 |
Why?
| | H-2 Antigens | 4 | 1992 | 115 | 0.160 |
Why?
| | Support Vector Machine | 2 | 2016 | 38 | 0.160 |
Why?
| | Islets of Langerhans Transplantation | 5 | 1992 | 63 | 0.160 |
Why?
| | Liver Cirrhosis, Experimental | 1 | 2019 | 11 | 0.160 |
Why?
| | Perilipin-2 | 1 | 2019 | 41 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2024 | 377 | 0.150 |
Why?
| | Cell Transformation, Viral | 2 | 1997 | 25 | 0.150 |
Why?
| | Antineoplastic Agents | 5 | 2013 | 2044 | 0.140 |
Why?
| | Indoles | 2 | 2013 | 386 | 0.140 |
Why?
| | Nephrectomy | 3 | 2014 | 158 | 0.140 |
Why?
| | Tumor Burden | 2 | 2017 | 286 | 0.140 |
Why?
| | Histocompatibility Antigens | 4 | 1988 | 107 | 0.140 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2018 | 208 | 0.140 |
Why?
| | Amyloid beta-Peptides | 5 | 2000 | 211 | 0.140 |
Why?
| | Hepatocytes | 1 | 2019 | 215 | 0.140 |
Why?
| | Factor X Deficiency | 1 | 1997 | 3 | 0.140 |
Why?
| | Rodenticides | 1 | 1997 | 4 | 0.140 |
Why?
| | Hydatidiform Mole | 1 | 1997 | 3 | 0.140 |
Why?
| | Colonic Pouches | 1 | 2017 | 14 | 0.140 |
Why?
| | Pregnancy, High-Risk | 1 | 1997 | 14 | 0.140 |
Why?
| | 4-Hydroxycoumarins | 1 | 1997 | 4 | 0.140 |
Why?
| | Graft Survival | 5 | 1996 | 514 | 0.130 |
Why?
| | Arrhythmias, Cardiac | 1 | 2019 | 321 | 0.130 |
Why?
| | Sensitivity and Specificity | 3 | 2016 | 1844 | 0.130 |
Why?
| | Maternal Age | 1 | 1997 | 125 | 0.130 |
Why?
| | Genital Neoplasms, Male | 1 | 2016 | 5 | 0.130 |
Why?
| | Granular Cell Tumor | 1 | 2016 | 7 | 0.130 |
Why?
| | HIV Seropositivity | 1 | 1997 | 119 | 0.130 |
Why?
| | alpha-Amylases | 4 | 1995 | 16 | 0.130 |
Why?
| | Scrotum | 1 | 2016 | 26 | 0.130 |
Why?
| | Adult | 18 | 2024 | 35607 | 0.130 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2019 | 381 | 0.130 |
Why?
| | Uterine Neoplasms | 1 | 1997 | 100 | 0.120 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2019 | 260 | 0.120 |
Why?
| | Blood Coagulation | 1 | 1997 | 239 | 0.120 |
Why?
| | Cystotomy | 1 | 2014 | 4 | 0.120 |
Why?
| | Prostatitis | 1 | 2014 | 18 | 0.110 |
Why?
| | Rectal Neoplasms | 1 | 2015 | 134 | 0.110 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2014 | 40 | 0.110 |
Why?
| | Muscle, Smooth | 1 | 2015 | 160 | 0.110 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2014 | 54 | 0.110 |
Why?
| | Incidence | 3 | 2014 | 2644 | 0.110 |
Why?
| | Enzyme Inhibitors | 2 | 2007 | 827 | 0.110 |
Why?
| | Female | 23 | 2024 | 68751 | 0.110 |
Why?
| | Optics and Photonics | 1 | 2014 | 43 | 0.110 |
Why?
| | Risk Assessment | 2 | 2020 | 3260 | 0.110 |
Why?
| | Adrenergic beta-Agonists | 2 | 1995 | 133 | 0.110 |
Why?
| | Colonic Neoplasms | 1 | 2015 | 241 | 0.100 |
Why?
| | Marijuana Smoking | 1 | 1997 | 247 | 0.100 |
Why?
| | Neurons | 6 | 1999 | 1509 | 0.100 |
Why?
| | Spectrometry, Fluorescence | 1 | 2014 | 164 | 0.100 |
Why?
| | Treatment Outcome | 4 | 2017 | 10221 | 0.100 |
Why?
| | Mice | 23 | 2019 | 16982 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 4 | 2017 | 2510 | 0.100 |
Why?
| | Tumor Cells, Cultured | 8 | 2000 | 930 | 0.100 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2012 | 13 | 0.100 |
Why?
| | Animals | 33 | 2019 | 35404 | 0.100 |
Why?
| | Abortion, Habitual | 1 | 1992 | 4 | 0.100 |
Why?
| | Antibodies, Anticardiolipin | 1 | 1992 | 8 | 0.100 |
Why?
| | Bone Neoplasms | 1 | 2015 | 229 | 0.100 |
Why?
| | Culture Media | 4 | 1994 | 162 | 0.100 |
Why?
| | Prostatic Intraepithelial Neoplasia | 2 | 2014 | 11 | 0.100 |
Why?
| | Niacinamide | 1 | 2013 | 75 | 0.100 |
Why?
| | Lymphatic Metastasis | 3 | 2024 | 320 | 0.100 |
Why?
| | Phenylurea Compounds | 1 | 2013 | 88 | 0.100 |
Why?
| | Aged, 80 and over | 7 | 2024 | 7064 | 0.100 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 259 | 0.100 |
Why?
| | Immune Tolerance | 2 | 1992 | 356 | 0.090 |
Why?
| | Angiomyolipoma | 1 | 2011 | 17 | 0.090 |
Why?
| | Organ Culture Techniques | 2 | 1992 | 155 | 0.090 |
Why?
| | Sarcoma | 1 | 2013 | 175 | 0.090 |
Why?
| | Vascular Neoplasms | 1 | 2011 | 17 | 0.090 |
Why?
| | Triiodothyronine | 1 | 2011 | 44 | 0.090 |
Why?
| | Immunoglobulin M | 1 | 1992 | 276 | 0.090 |
Why?
| | Immunoglobulin A | 1 | 1992 | 201 | 0.090 |
Why?
| | HIV-1 | 1 | 1997 | 838 | 0.090 |
Why?
| | Follow-Up Studies | 3 | 2014 | 4892 | 0.090 |
Why?
| | Thyroxine | 1 | 2011 | 62 | 0.090 |
Why?
| | Hypothyroidism | 1 | 2011 | 70 | 0.090 |
Why?
| | NF-kappa B | 1 | 2014 | 666 | 0.090 |
Why?
| | Thrombocytopenia | 1 | 1992 | 189 | 0.090 |
Why?
| | Mice, Inbred Strains | 6 | 1992 | 408 | 0.090 |
Why?
| | Antigens | 1 | 1992 | 356 | 0.080 |
Why?
| | Recombinant Fusion Proteins | 1 | 2012 | 650 | 0.080 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 1992 | 247 | 0.080 |
Why?
| | Smoking | 3 | 1997 | 1502 | 0.080 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2013 | 503 | 0.080 |
Why?
| | Rats | 12 | 2000 | 5485 | 0.080 |
Why?
| | Organ Size | 3 | 2019 | 456 | 0.080 |
Why?
| | Cystitis | 1 | 2009 | 22 | 0.080 |
Why?
| | Thrombosis | 1 | 1992 | 349 | 0.080 |
Why?
| | Neurotoxins | 2 | 1998 | 28 | 0.070 |
Why?
| | Referral and Consultation | 2 | 2011 | 735 | 0.070 |
Why?
| | Cyclosporine | 2 | 2000 | 263 | 0.070 |
Why?
| | Cohort Studies | 3 | 2020 | 5434 | 0.070 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1990 | 363 | 0.070 |
Why?
| | Immunoglobulin G | 1 | 1992 | 851 | 0.070 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 2008 | 21 | 0.070 |
Why?
| | Intestinal Perforation | 1 | 2008 | 45 | 0.070 |
Why?
| | Transplantation Immunology | 1 | 1988 | 34 | 0.070 |
Why?
| | Graft Enhancement, Immunologic | 1 | 1987 | 1 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 3 | 2015 | 3394 | 0.070 |
Why?
| | Chemoprevention | 1 | 2008 | 91 | 0.070 |
Why?
| | Radionuclide Imaging | 1 | 2007 | 122 | 0.070 |
Why?
| | Minor Histocompatibility Loci | 1 | 1987 | 4 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 4 | 2013 | 377 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 886 | 0.070 |
Why?
| | Anticarcinogenic Agents | 1 | 2007 | 77 | 0.070 |
Why?
| | Kidney Diseases, Cystic | 1 | 2006 | 21 | 0.070 |
Why?
| | Staining and Labeling | 3 | 2013 | 143 | 0.070 |
Why?
| | Risk Factors | 3 | 2019 | 9787 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 6 | 1998 | 2403 | 0.060 |
Why?
| | Obesity | 1 | 2019 | 2885 | 0.060 |
Why?
| | Amyloid beta-Protein Precursor | 3 | 2000 | 61 | 0.060 |
Why?
| | Transplantation, Homologous | 5 | 1992 | 402 | 0.060 |
Why?
| | Syndrome | 2 | 2021 | 337 | 0.060 |
Why?
| | Cell Differentiation | 5 | 2000 | 1900 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 1997 | 2104 | 0.060 |
Why?
| | Cell Line, Transformed | 4 | 1998 | 139 | 0.060 |
Why?
| | Survival Rate | 2 | 2000 | 1872 | 0.060 |
Why?
| | Dopamine | 2 | 1998 | 286 | 0.060 |
Why?
| | Culture Techniques | 3 | 1990 | 81 | 0.050 |
Why?
| | Alprostadil | 3 | 1999 | 32 | 0.050 |
Why?
| | Observer Variation | 2 | 2015 | 314 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2024 | 646 | 0.050 |
Why?
| | Liver | 1 | 2011 | 1839 | 0.050 |
Why?
| | Image Interpretation, Computer-Assisted | 2 | 2015 | 252 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 1 | 2024 | 851 | 0.050 |
Why?
| | Neoadjuvant Therapy | 1 | 2024 | 379 | 0.050 |
Why?
| | Reproducibility of Results | 3 | 2014 | 3084 | 0.050 |
Why?
| | CD4 Antigens | 2 | 1992 | 137 | 0.050 |
Why?
| | Remission, Spontaneous | 1 | 2021 | 38 | 0.050 |
Why?
| | Time Factors | 3 | 2000 | 6545 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2021 | 121 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 1992 | 170 | 0.040 |
Why?
| | Lung Diseases, Interstitial | 1 | 2006 | 611 | 0.040 |
Why?
| | Aluminum | 1 | 2000 | 39 | 0.040 |
Why?
| | Histiocytic Necrotizing Lymphadenitis | 1 | 1999 | 2 | 0.040 |
Why?
| | Peptidylprolyl Isomerase | 1 | 1999 | 11 | 0.040 |
Why?
| | Angiolymphoid Hyperplasia with Eosinophilia | 1 | 1999 | 2 | 0.040 |
Why?
| | Parotid Diseases | 1 | 1999 | 5 | 0.040 |
Why?
| | Perineum | 1 | 2019 | 26 | 0.040 |
Why?
| | RNA, Messenger | 6 | 1999 | 2702 | 0.040 |
Why?
| | Adenylyl Cyclases | 2 | 1996 | 83 | 0.040 |
Why?
| | Retrospective Studies | 2 | 2015 | 14525 | 0.040 |
Why?
| | Fetal Tissue Transplantation | 1 | 1998 | 35 | 0.040 |
Why?
| | Prostaglandins | 1 | 1998 | 94 | 0.040 |
Why?
| | Cells, Cultured | 7 | 1998 | 4102 | 0.040 |
Why?
| | Prostaglandins A | 1 | 1998 | 10 | 0.040 |
Why?
| | Lung Neoplasms | 2 | 2009 | 2343 | 0.040 |
Why?
| | Radiometry | 1 | 2018 | 47 | 0.040 |
Why?
| | Growth Inhibitors | 1 | 1998 | 42 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2018 | 251 | 0.040 |
Why?
| | CD8 Antigens | 3 | 1992 | 75 | 0.040 |
Why?
| | Adenoma | 1 | 2000 | 213 | 0.040 |
Why?
| | Genes, p53 | 1 | 1997 | 70 | 0.030 |
Why?
| | Lung Diseases, Obstructive | 1 | 1997 | 46 | 0.030 |
Why?
| | Mice, Inbred C57BL | 4 | 2019 | 5468 | 0.030 |
Why?
| | Salvage Therapy | 1 | 2018 | 136 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2019 | 239 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 129 | 0.030 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 1997 | 47 | 0.030 |
Why?
| | Vitamin K 1 | 1 | 1997 | 3 | 0.030 |
Why?
| | Chorionic Gonadotropin, beta Subunit, Human | 1 | 1997 | 15 | 0.030 |
Why?
| | Prothrombin Time | 1 | 1997 | 33 | 0.030 |
Why?
| | Adolescent | 6 | 2016 | 20415 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 1999 | 457 | 0.030 |
Why?
| | Blood Coagulation Factors | 1 | 1997 | 53 | 0.030 |
Why?
| | Point Mutation | 1 | 1997 | 224 | 0.030 |
Why?
| | Isoproterenol | 2 | 1994 | 116 | 0.030 |
Why?
| | Alzheimer Disease | 2 | 2000 | 516 | 0.030 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 1996 | 71 | 0.030 |
Why?
| | Mesencephalon | 1 | 1996 | 66 | 0.030 |
Why?
| | Colon, Ascending | 1 | 2015 | 3 | 0.030 |
Why?
| | Hysterectomy | 1 | 1997 | 118 | 0.030 |
Why?
| | Bronchi | 1 | 1997 | 249 | 0.030 |
Why?
| | Glioma | 1 | 2000 | 351 | 0.030 |
Why?
| | Thyroid Neoplasms | 1 | 2000 | 311 | 0.030 |
Why?
| | Brain | 2 | 1998 | 2677 | 0.030 |
Why?
| | Islets of Langerhans | 3 | 1992 | 791 | 0.030 |
Why?
| | Mouth Mucosa | 1 | 1996 | 89 | 0.030 |
Why?
| | Corpus Striatum | 1 | 1997 | 154 | 0.030 |
Why?
| | 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone | 3 | 2000 | 3 | 0.030 |
Why?
| | Lymphocytes | 2 | 1988 | 377 | 0.030 |
Why?
| | Neoplasms | 1 | 1989 | 2454 | 0.030 |
Why?
| | Membrane Transport Proteins | 1 | 1996 | 149 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2000 | 858 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2019 | 594 | 0.030 |
Why?
| | Patient Selection | 1 | 2018 | 660 | 0.030 |
Why?
| | Prostatic Hyperplasia | 1 | 2015 | 41 | 0.030 |
Why?
| | Genetic Variation | 1 | 2019 | 937 | 0.030 |
Why?
| | Adenoma, Pleomorphic | 1 | 1994 | 10 | 0.030 |
Why?
| | Parotid Neoplasms | 1 | 1994 | 16 | 0.030 |
Why?
| | Mice, Inbred BALB C | 3 | 1989 | 1248 | 0.030 |
Why?
| | Wavelet Analysis | 1 | 2014 | 6 | 0.030 |
Why?
| | Atrophy | 1 | 2014 | 170 | 0.030 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 2 | 1991 | 88 | 0.030 |
Why?
| | Least-Squares Analysis | 1 | 2014 | 79 | 0.030 |
Why?
| | Terbutaline | 1 | 1993 | 8 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 1996 | 477 | 0.030 |
Why?
| | Breeding | 1 | 2013 | 61 | 0.030 |
Why?
| | beta-Galactosidase | 1 | 2013 | 77 | 0.030 |
Why?
| | Needles | 1 | 2014 | 57 | 0.030 |
Why?
| | Dobutamine | 1 | 1993 | 37 | 0.030 |
Why?
| | Autopsy | 1 | 2013 | 92 | 0.030 |
Why?
| | Glucose | 1 | 2019 | 1003 | 0.030 |
Why?
| | Phenotype | 2 | 2019 | 3062 | 0.030 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2014 | 98 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 2 | 1992 | 412 | 0.030 |
Why?
| | Hyperplasia | 1 | 2013 | 175 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2012 | 32 | 0.030 |
Why?
| | Keratins | 1 | 2013 | 175 | 0.030 |
Why?
| | Organ Specificity | 1 | 2013 | 295 | 0.030 |
Why?
| | Kallikreins | 1 | 2012 | 29 | 0.030 |
Why?
| | Integrases | 1 | 2013 | 119 | 0.030 |
Why?
| | Adenoviridae | 1 | 2013 | 193 | 0.020 |
Why?
| | Parkinson Disease | 1 | 1998 | 462 | 0.020 |
Why?
| | Lymphocyte Activation | 3 | 1992 | 1110 | 0.020 |
Why?
| | Health Surveys | 1 | 2014 | 494 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 1996 | 569 | 0.020 |
Why?
| | Pregnancy | 2 | 1997 | 6412 | 0.020 |
Why?
| | RNA, Untranslated | 1 | 2013 | 117 | 0.020 |
Why?
| | T-Lymphocytes | 2 | 1991 | 1937 | 0.020 |
Why?
| | Sex Factors | 2 | 2015 | 1973 | 0.020 |
Why?
| | Equipment Design | 1 | 2014 | 514 | 0.020 |
Why?
| | Minor Histocompatibility Antigens | 1 | 1992 | 46 | 0.020 |
Why?
| | Antigens, CD | 1 | 2014 | 487 | 0.020 |
Why?
| | Clone Cells | 3 | 1996 | 262 | 0.020 |
Why?
| | Cell Line | 2 | 1994 | 2779 | 0.020 |
Why?
| | Macrophages | 1 | 2019 | 1489 | 0.020 |
Why?
| | Actins | 1 | 1993 | 410 | 0.020 |
Why?
| | Age Factors | 2 | 2015 | 3153 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1168 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 1992 | 836 | 0.020 |
Why?
| | Cocarcinogenesis | 1 | 1989 | 14 | 0.020 |
Why?
| | Lymphokines | 1 | 1990 | 127 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 808 | 0.020 |
Why?
| | Proteins | 1 | 1995 | 944 | 0.020 |
Why?
| | Inflammation | 2 | 1998 | 2748 | 0.020 |
Why?
| | Laparoscopy | 1 | 2014 | 447 | 0.020 |
Why?
| | Phosphodiesterase Inhibitors | 2 | 2000 | 89 | 0.020 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 1991 | 183 | 0.020 |
Why?
| | Recurrence | 1 | 1992 | 1012 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2012 | 605 | 0.020 |
Why?
| | Beverages | 1 | 1989 | 68 | 0.020 |
Why?
| | Nephrolithiasis | 1 | 2009 | 10 | 0.020 |
Why?
| | Computer Simulation | 1 | 2013 | 940 | 0.020 |
Why?
| | Metaplasia | 1 | 2009 | 57 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 1992 | 382 | 0.020 |
Why?
| | Interferon-gamma | 2 | 1990 | 773 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2011 | 610 | 0.020 |
Why?
| | Interferons | 1 | 1990 | 189 | 0.020 |
Why?
| | Odds Ratio | 1 | 2011 | 1021 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 5083 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1829 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2014 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2009 | 282 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2135 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1506 | 0.020 |
Why?
| | Placebos | 1 | 2008 | 201 | 0.020 |
Why?
| | Cisplatin | 1 | 2009 | 299 | 0.020 |
Why?
| | Immunologic Memory | 1 | 1990 | 349 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1500 | 0.020 |
Why?
| | Histocompatibility Antigens Class I | 1 | 1989 | 200 | 0.020 |
Why?
| | Bucladesine | 2 | 1998 | 25 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 1950 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2012 | 4076 | 0.020 |
Why?
| | Medical History Taking | 1 | 2007 | 118 | 0.020 |
Why?
| | Bias | 1 | 2007 | 197 | 0.020 |
Why?
| | Kidney Transplantation | 1 | 1992 | 670 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1987 | 541 | 0.020 |
Why?
| | Endocrine Glands | 1 | 1986 | 15 | 0.020 |
Why?
| | Pedigree | 1 | 2007 | 483 | 0.020 |
Why?
| | Radiography | 1 | 2008 | 797 | 0.020 |
Why?
| | Physicians | 1 | 2014 | 871 | 0.020 |
Why?
| | Culture Media, Serum-Free | 2 | 1998 | 49 | 0.020 |
Why?
| | Hypersensitivity, Delayed | 1 | 1985 | 28 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3184 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2012 | 2378 | 0.010 |
Why?
| | Cell Survival | 1 | 1988 | 1086 | 0.010 |
Why?
| | Antigen-Presenting Cells | 1 | 1985 | 151 | 0.010 |
Why?
| | Early Detection of Cancer | 1 | 2008 | 371 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 956 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2011 | 3381 | 0.010 |
Why?
| | Testosterone | 1 | 2007 | 372 | 0.010 |
Why?
| | Young Adult | 1 | 2020 | 12457 | 0.010 |
Why?
| | Alcohol Drinking | 1 | 1989 | 764 | 0.010 |
Why?
| | Cross Reactions | 1 | 1983 | 133 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 1983 | 271 | 0.010 |
Why?
| | Colorado | 1 | 2012 | 4405 | 0.010 |
Why?
| | Logistic Models | 1 | 2007 | 1988 | 0.010 |
Why?
| | Lymphocyte Depletion | 2 | 1992 | 134 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1560 | 0.010 |
Why?
| | Transfection | 2 | 1994 | 918 | 0.010 |
Why?
| | Prospective Studies | 1 | 2012 | 7145 | 0.010 |
Why?
| | Alum Compounds | 1 | 2000 | 22 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 1983 | 672 | 0.010 |
Why?
| | Neurites | 1 | 2000 | 47 | 0.010 |
Why?
| | Carotenoids | 1 | 1999 | 41 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2007 | 2739 | 0.010 |
Why?
| | Neck | 1 | 1999 | 95 | 0.010 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 1997 | 27 | 0.010 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1997 | 66 | 0.010 |
Why?
| | Codon | 1 | 1997 | 84 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 953 | 0.010 |
Why?
| | Simian virus 40 | 1 | 1996 | 23 | 0.010 |
Why?
| | Epithelium | 1 | 1997 | 311 | 0.010 |
Why?
| | Transplantation, Heterotopic | 1 | 1996 | 18 | 0.010 |
Why?
| | Butyric Acid | 1 | 1996 | 6 | 0.010 |
Why?
| | Xerostomia | 1 | 1996 | 17 | 0.010 |
Why?
| | Oxidopamine | 1 | 1996 | 13 | 0.010 |
Why?
| | 3,4-Dihydroxyphenylacetic Acid | 1 | 1996 | 19 | 0.010 |
Why?
| | Protein Kinase C beta | 1 | 1996 | 21 | 0.010 |
Why?
| | Carbocyanines | 1 | 1996 | 33 | 0.010 |
Why?
| | Phosphopyruvate Hydratase | 1 | 1996 | 26 | 0.010 |
Why?
| | Stereotyped Behavior | 1 | 1996 | 19 | 0.010 |
Why?
| | Exons | 1 | 1997 | 341 | 0.010 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 1996 | 31 | 0.010 |
Why?
| | Nestin | 1 | 1996 | 19 | 0.010 |
Why?
| | Intermediate Filament Proteins | 1 | 1996 | 57 | 0.010 |
Why?
| | Protein Kinase C-delta | 1 | 1996 | 44 | 0.010 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 1996 | 47 | 0.010 |
Why?
| | Proline-Rich Protein Domains | 1 | 1995 | 2 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1992 | 3629 | 0.010 |
Why?
| | Muscarinic Agonists | 1 | 1995 | 16 | 0.010 |
Why?
| | Salivary Proteins and Peptides | 1 | 1995 | 14 | 0.010 |
Why?
| | Adrenergic alpha-Agonists | 1 | 1995 | 28 | 0.010 |
Why?
| | Cells, Immobilized | 1 | 1995 | 21 | 0.010 |
Why?
| | Peptide Fragments | 1 | 2000 | 695 | 0.010 |
Why?
| | Butyrates | 1 | 1996 | 57 | 0.010 |
Why?
| | Methamphetamine | 1 | 1996 | 55 | 0.010 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1996 | 127 | 0.010 |
Why?
| | Isoenzymes | 1 | 1996 | 301 | 0.010 |
Why?
| | Immunoblotting | 1 | 1995 | 306 | 0.010 |
Why?
| | Antibodies, Monoclonal | 2 | 1992 | 1368 | 0.010 |
Why?
| | Protein Kinase C | 1 | 1996 | 262 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 1996 | 313 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1994 | 253 | 0.010 |
Why?
| | Chronic Disease | 1 | 1999 | 1723 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 1992 | 134 | 0.010 |
Why?
| | Kinetics | 1 | 1996 | 1645 | 0.010 |
Why?
| | Feasibility Studies | 1 | 1996 | 869 | 0.010 |
Why?
| | Mice, Nude | 1 | 1994 | 680 | 0.010 |
Why?
| | Carrier Proteins | 1 | 1996 | 741 | 0.010 |
Why?
| | Blotting, Western | 1 | 1994 | 1204 | 0.010 |
Why?
| | Plasmids | 1 | 1992 | 360 | 0.010 |
Why?
| | Models, Biological | 2 | 1991 | 1724 | 0.010 |
Why?
| | Mice, Inbred NOD | 1 | 1992 | 587 | 0.010 |
Why?
| | Spleen | 1 | 1992 | 508 | 0.010 |
Why?
| | United States | 1 | 2007 | 13906 | 0.010 |
Why?
| | Mice, Mutant Strains | 1 | 1991 | 298 | 0.010 |
Why?
| | Interleukin-3 | 1 | 1990 | 23 | 0.010 |
Why?
| | Peptides | 1 | 1995 | 926 | 0.010 |
Why?
| | Cohort Effect | 1 | 1989 | 4 | 0.010 |
Why?
| | Cacao | 1 | 1989 | 7 | 0.010 |
Why?
| | Coffee | 1 | 1989 | 15 | 0.010 |
Why?
| | Tea | 1 | 1989 | 20 | 0.010 |
Why?
| | Flow Cytometry | 1 | 1992 | 1160 | 0.000 |
Why?
| | Interleukin-2 | 1 | 1990 | 437 | 0.000 |
Why?
| | Epithelial Cells | 1 | 1992 | 1063 | 0.000 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1990 | 1204 | 0.000 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1990 | 1058 | 0.000 |
Why?
| | Blood Glucose | 1 | 1992 | 2102 | 0.000 |
Why?
| | Infant, Newborn | 1 | 1989 | 5759 | 0.000 |
Why?
| | Infant | 1 | 1989 | 8987 | 0.000 |
Why?
| | Child, Preschool | 1 | 1989 | 10487 | 0.000 |
Why?
| | Child | 1 | 1989 | 20882 | 0.000 |
Why?
|
|
La Rosa's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|